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The proportion of tuberculosis (TB) cases in Europe occurring in migrants is increasing. 19 
Extrapulmonary TB poses challenges in diagnosis and treatment and causes serious morbidity 20 
and mortality, yet its extent in migrant populations is unclear. We assessed patterns of 21 
extrapulmonary TB in migrants across the European Union (EU)/European Free Trade 22 
Association (EFTA). We investigated the proportion of extrapulmonary TB cases among migrants 23 
versus non-migrants, and variations by specific site of disease, reporting European region, and 24 
migrant region of origin. 25 
Methods 26 
We carried out a cross-sectional secondary database analysis, utilising 23 years of data from the 27 
European Centre for Disease Prevention and Control’s European Surveillance System for 32 28 
EU/EFTA countries collected 1995-2017.  29 
Results 30 
1,270,896 TB cases were included, comprising 326,987 (25.7%) migrants and 943,909 (74.3%) 31 
non-migrants. 45.2% (n=147,814) of TB cases among migrants were extrapulmonary, compared 32 
to 21.7% (n=204,613) among non-migrants (p<0.001). Lymphatic, bone/joint and 33 
peritoneal/digestive TB were more common among migrant than non-migrant extrapulmonary 34 
cases. A lower proportion of extrapulmonary TB was seen in Eastern (17.4%, n=98,656 of 35 








of 250,517) and Northern (41.8%, n=101,792 of 243,381) Europe. Migrants from South-East Asia 37 
and Sub-Saharan Africa were at highest risk of extrapulmonary disease, with 62.0% (n=55,401 of 38 
89,353) and 54.5% (n=38,327 of 70,378) of cases respectively being extrapulmonary.  39 
Conclusions 40 
Among TB cases in the EU/EFTA, extrapulmonary disease is significantly more common in 41 
migrants than non-migrants. There is a need to improve clinical awareness of extrapulmonary 42 










The proportion of tuberculosis (TB) cases in migrants has been rising across high-income 45 
countries in Europe [1] and the United States (US) [2]. In 2017, migrants comprised 33.1% of TB 46 
cases across European Union/European Economic Area (EU/EEA) countries, and over 70% in 47 
parts of Northern and Western Europe [3]. This trend is set to continue, as TB notification rates 48 
are falling faster in native-born residents than those of foreign origin in the EU/EEA [4]. In 49 
addition, migrant populations in high-income countries are growing, with 4.4 million people 50 
migrating to an EU Member State during 2017 [5].  51 
While TB most commonly affects the lungs, it can present in almost any organ of the body, 52 
including the lymph nodes, pleura, central nervous system (CNS), bones and joints, genito-53 
urinary tract and gastro-intestinal system [6], or disseminated as miliary TB [7]. While not 54 
usually transmissible, extrapulmonary TB can cause serious morbidity and mortality. It is more 55 
common among immunosuppressed individuals, such as those with HIV/AIDS. Extrapulmonary 56 
TB poses challenges in diagnosis and treatment, due to its wide variety of non-specific clinical 57 
presentations [8].  58 
Globally, 15% of the 7 million incident TB cases notified in 2018 were extrapulmonary [9]. 59 
Despite this, extrapulmonary TB is rarely specifically incorporated into TB control programmes, 60 
including those targeting migrants. Current guidance from the European Centre for Disease 61 
Prevention and Control (ECDC) recommends screening for active pulmonary TB using chest X-62 









interferon-gamma release assay (IGRA) soon after migrants from high TB incidence countries 64 
arrive in the EU/EEA [10], with no specific provision for detecting extrapulmonary disease.  65 
Patterns of extrapulmonary TB in migrants are not well-understood, despite implications for 66 
morbidity and mortality. We aim to assess patterns of extrapulmonary TB in migrants in 67 
EU/European Free Trade Association (EFTA) countries through analysis of ECDC’s European 68 
Surveillance System (TESSy) database. The specific objectives are to examine whether the 69 
proportion of extrapulmonary TB cases is greater in migrants compared with non-migrants, 70 
which specific sites of extrapulmonary disease are more or less common in migrants, and how 71 
the distribution of cases varies by European reporting region and migrants’ region of origin. 72 
 73 
Methods 74 
Data and definitions 75 
We analysed 23 years of data from ECDC’s TESSy database for 32 EU/EFTA countries (henceforth 76 
‘Europe’) collected from inception in 1995 to 2017. Detailed data collection methods and 77 
definitions have been described [3]. In brief, designated experts within national surveillance 78 
institutes submit case-based data to TESSy, where a TB case is defined following the World 79 
Health Organization (WHO) as a bacteriologically confirmed or clinically diagnosed case [11]. 80 









The analysis was restricted to TB cases with known migrant status and site of TB. We define a 82 
migrant as a person born in, or having citizenship of, a country different to the reporting 83 
country. Extrapulmonary TB is classified as a case involving organs or anatomical sites other 84 
than the lungs, with or without co-existent lung disease. Specific site of extrapulmonary TB was 85 
grouped as: lymphatic, pleural, bone/joint including spine, disseminated, genito-urinary, 86 
peritoneal/digestive, CNS including meningitis, and other. Region of Europe was defined using 87 
the United Nations Geoscheme for Europe: Eastern, Northern, Southern and Western [12]. 88 
Region of origin was defined using an adaptation of World Bank regions: Eastern Europe and 89 
Central Asia, Europe, North America and Oceania, Latin America and the Caribbean, Middle East 90 
and North Africa, South-East Asia, and Sub-Saharan Africa [13]. Definitions are presented in 91 
Figure S1. 92 
Statistical methods 93 
We assessed how key demographic characteristics differed between migrants and non-94 
migrants, using t tests for continuous variables and chi-square tests for categorical variables. We 95 
compared the difference in proportion of extrapulmonary TB between migrants and non-96 
migrants using chi-square tests. We repeated this analysis in subgroups, firstly dividing the 97 
sample into drug susceptible and multi-drug resistant (MDR)-TB (defined as resistance to at 98 
least isoniazid and rifampicin), and secondly dividing the study period in two (1995-2006 and 99 
2007-2017). In addition, we used two-sample tests of proportion to compare the difference in 100 
proportion of extrapulmonary TB at a given site between migrants and non-migrants, chi-square 101 









Europe, and one-sample tests of proportion to compare the difference in proportion of 103 
pulmonary versus extrapulmonary TB in each migrant region of origin. In sensitivity analyses, we 104 
repeated these analyses defining extrapulmonary TB as cases involving only organs or 105 
anatomical sites other than the lungs. A p value of p<0.01 was considered statistically 106 
significant. All analyses were conducted in StataSE v15. 107 
Ethical statement 108 
The study was based on data collected on the basis of statutory notification in each EU/EFTA 109 
country and reported anonymously to ECDC per decision No 2119/98/EC of the European 110 
Parliament and of the Council.  111 
 112 
Results 113 
Sample characteristics 114 
1,611,762 TB cases were notified in the EU/EFTA between 1995-2017 and reported in TESSy, of 115 
which 1,270,896 (78.9%) had data available on migrant status and site of TB and were included 116 
in the analyses (Figure 1). The included sample comprises 326,987 (25.7%) migrants and 117 
943,909 (74.3%) non-migrants. Migrant regions of origin and destination are shown in Figure S2, 118 
and sample characteristics by migrant status are presented in Table 1.  119 
The mean age of included migrants with TB is 38 years compared with 48 years in non-migrants 120 









(n=622,902 of 943,438) of non-migrants (p<0.001). Migrant TB cases in the EU/EFTA originate 122 
from diverse areas of the world, most commonly South-East Asia (34.2%, n=89,303 of 261,074) 123 
and Sub-Saharan Africa (26.9%, n=70,341). The most common countries of origin for migrants 124 
with TB are India (n=30,174), Pakistan (n=23,081), Somalia (n=20,453), and Romania (n=14,620). 125 
In Eastern and Southern Europe, the majority of TB cases are in non-migrants, whereas in 126 
Northern and Western Europe around half are in migrants. Migrants were reported to be less 127 
likely than non-migrants to have been previously diagnosed with TB (p<0.001).   128 
Extrapulmonary TB in migrants 129 
The proportion of TB that is extrapulmonary is significantly greater among migrants than non-130 
migrants (Figure 2): 45.2% (n=147,814 of 326,987) of cases among migrants were 131 
extrapulmonary, compared to 21.7% (n=204,613 of 943,909) among non-migrants (p<0.001). 132 
This pattern is seen in both drug susceptible and MDR-TB (both p<0.001), and in the earlier 133 
(1995-2006) and later (2007-2017) parts of the study period (both p<0.001, Table S1).  134 
Among extrapulmonary TB cases, specific site varies by migrant status (Table 2). For migrants, 135 
47.6% (n=37,150 of 78,077) of extrapulmonary TB is lymphatic, compared with 25.3% (n=43,933 136 
of 173,604) in non-migrants (p<0.001). This varies by country of origin, e.g. among migrants 137 
from India, 52.4% (n=2,079 of 3,971) of extrapulmonary TB is lymphatic. Conversely, 17.6% 138 
(n=13,730 of 78,077) of extrapulmonary TB is pleural in migrants versus 42.1% (n=73,052 of 139 
173,604) in non-migrants (p<0.001). 24,965 TB cases (4,336 migrants and 20,629 non-migrants) 140 
were reported to include both pulmonary and pleural involvement. Differences are also seen for 141 









in migrants than in non-migrants, and genito-urinary TB (p<0.001), which is less common in 143 
migrants.  144 
Extrapulmonary TB by European reporting region 145 
A relatively low proportion of extrapulmonary TB is seen in Eastern (17.4%, n=98,656 of 146 
566,170) and Southern (29.6%, n=62,481 of 210,828) Europe compared with Western (35.7%, 147 
n=89,498 of 250,517) and Northern (41.8%, n=101,792 of 243,381) Europe (Table 3). Migrants 148 
are reported to have a greater proportion of extrapulmonary TB than non-migrants only in 149 
Western and Northern Europe (both p<0.001). For example, in Northern Europe, 58.5% of TB 150 
(n=72,868 of 124,547) is extrapulmonary among migrant cases compared with 24.3% (n=28,924 151 
of 118,834) among non-migrants (p<0.001). Figure 3 shows that in Northern and Western 152 
European countries, a high proportion of TB occurs in migrants, with a particularly high 153 
proportion of extrapulmonary TB being among migrants. In Southern and Eastern European 154 
countries, a lower proportion of TB is in migrants, and this pattern does not differ markedly 155 
between pulmonary and extrapulmonary TB.  156 
Extrapulmonary TB and migrants’ region of origin 157 
Over half of TB cases are extrapulmonary among migrants from South-East Asia (62.0%, 158 
n=55,401 of 89,353, p<0.001) and Sub-Saharan Africa (54.5%, n=38,327 of 70,378, p<0.001) 159 
(Figure 4), which are the most common regions of origin for migrant TB cases in Europe. For 160 









In contrast, the proportion of reported extrapulmonary disease is particularly low among 162 
migrants from Eastern Europe and Central Asia (20.6%, n=11,576 of 56,310, p<0.001).  163 
Sensitivity analyses 164 
In sensitivity analyses, we established that these patterns are seen whether extrapulmonary TB 165 
is defined as any extrapulmonary or only extrapulmonary TB (Figures S3-4 and Tables S2-4). 166 
 167 
Discussion 168 
We found that the proportion of TB that is extrapulmonary is significantly greater among 169 
migrants than non-migrants. These data are consistent with single-country studies in the UK and 170 
Netherlands indicating that migrants are at increased risk of extrapulmonary TB [14, 15]. The 171 
reasons for this are not fully understood. At a time of rising migration to Europe and other high-172 
income countries, with a growing proportion of TB cases occurring in migrants [2, 5], 173 
extrapulmonary TB in this group is an increasingly important issue. Indeed, the reported 174 
proportion of extrapulmonary TB increased from 16.4% in 2002 to 22.4% in 2011 in the EU/EEA 175 
[16]. Extrapulmonary TB poses challenges in diagnosis and treatment, with implications for 176 
patient outcomes. Thus, migrants’ disproportionate burden of extrapulmonary TB may 177 
contribute to their worse treatment outcomes [17]. 178 
We found that specific site of extrapulmonary TB varies by migrant status. The reasons for this 179 









origin. For example, India has relatively high rates of lymphatic TB [18], a pattern mirrored 181 
among Indian migrants. Migrants were observed to have a lower proportion of pleural TB than 182 
non-migrants. However, this should be interpreted with caution, as many cases were reported 183 
to include both pulmonary and pleural involvement. Such cases may be classified as having 184 
pulmonary plus pleural disease (i.e. extrapulmonary), or as pulmonary disease only. Differences 185 
are also seen for other sites of TB (bone/joint, peritoneal/digestive, and genito-urinary). 186 
However, the absolute numbers of cases are low for these extrapulmonary sites, so a statistical 187 
difference may have relatively little clinical implication. These could also potentially be 188 
artefacts; for example, genito-urinary TB may be misdiagnosed as more common sexually 189 
transmitted infections or urinary tract infections, delaying TB diagnosis [19].  190 
We also found a higher proportion of extrapulmonary TB in Northern and Western Europe 191 
compared with Southern and especially Eastern Europe, with the disproportionate burden of 192 
extrapulmonary TB among migrants seen only in Northern and Western Europe. The reasons for 193 
this are unclear. Extrapulmonary TB is thought to usually follow reactivation of latent infection 194 
rather than occurring at initial infection, with the exception of TB meningitis [20]. Most migrant 195 
TB cases are infected before arrival in host countries, with subsequent reactivation of LTBI [21]. 196 
This is especially true in final destination, high-income countries of Northern and Western 197 
Europe, which may contribute to the higher prevalence of extrapulmonary TB in migrants in 198 
these regions. Transit countries in Southern and Eastern Europe may see a slightly higher 199 
proportion of migrants arriving with active TB or transmission, for example in refugee camps 200 
[22]. In addition, healthcare access for migrants varies significantly across Europe [23], and once 201 









systems, and more likely to seek care for symptoms of extrapulmonary TB. By contrast, public 203 
health initiatives targeting migrants in transit countries tend to focus on preventing the spread 204 
of pulmonary TB. However, even in final destination countries migrants often face significant 205 
barriers to healthcare access [24]; therefore this is unlikely to account fully for the observed 206 
differences across Europe.  207 
The proportion of extrapulmonary TB is highest among migrants from South-East Asia and Sub-208 
Saharan Africa. This is consistent with data from Germany and across the EU/EEA showing that 209 
migrant TB cases from Asia and Africa were more likely than non-migrant patients to present 210 
with extrapulmonary disease [25, 26]. Migrants from certain regions may be genetically 211 
predisposed to extrapulmonary manifestations of TB [14]. Some countries in Northern and 212 
Western Europe host large migrant populations from the Indian subcontinent, where 213 
extrapulmonary TB is relatively common [18]. Extrapulmonary TB is also more common in the 214 
immunosuppressed, including HIV/AIDS patients [27], and the high burden of TB-HIV co-215 
morbidity in Sub-Saharan Africa may contribute to increased risk of extrapulmonary TB [28]. 216 
However, TB-HIV co-morbidity accounts for a small proportion of TB cases in Europe, and 217 
therefore is unlikely to be a major driver of the observed patterns.  218 
Strengths and limitations 219 
By using surveillance data reported by EU/EFTA Member States to ECDC between 1995-2017, 220 
this study utilises data from over 1 million TB cases, enabling a comprehensive analysis of 221 
patterns of extrapulmonary TB in migrants across Europe. In all EU/EFTA countries, TB is a 222 









systems, and there are gaps in reporting. 340,866 TB cases were excluded from our analyses 224 
because they lacked data on either migrant status or site of TB. The proportion of all notified TB 225 
cases that have this data available, and are therefore included, increases over time, from below 226 
50% until 2001 to over 80% from 2002 and over 90% since 2004 (Table S5). 227 
Most co-variates have good completeness in our dataset (Table S6). Age, gender, and reporting 228 
country are over 99% complete, country of origin is 90% complete, previous TB diagnosis is 229 
~85% complete, and site of TB among extrapulmonary cases is ~70% complete. However, HIV 230 
status was only collected from 2000 onwards, meaning that in our sample only 17% of cases had 231 
data on HIV status. This potentially important variable was therefore excluded from analyses. 232 
The limited nature of the data available prevented us from unpicking the relative impact of host 233 
and environmental factors and M.tb lineage. This, and the pattern of drug resistance in relation 234 
to migration status and site of TB, warrants further investigation. Furthermore, migrant status is 235 
defined by country of birth in some countries and country of citizenship in others, which may 236 
influence the findings.  237 
Implications 238 
The findings have important clinical implications for migrant-receiving countries, particularly in 239 
Northern and Western Europe. Although there are many reports and guidelines relating to 240 
managing TB and migrant health, none adequately address the key issues arising from 241 
extrapulmonary TB in this group. There is a need to improve diagnostic facilities and awareness 242 
of extrapulmonary TB among healthcare staff, particularly when assessing patients from South-243 








integrated into screening programmes, with a focus on migrants. Extrapulmonary TB must be 245 
considered when screening for latent as well as active disease, when it is essential to ascertain 246 
that patients do not have active extrapulmonary disease before initiating preventative 247 
chemoprophylaxis for LTBI. Programmes that target migrants for LTBI screening and treatment 248 
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Figure 1. Sample flow chart 328 
EU/EFTA: European Union/European Free Trade Association, TB: tuberculosis 329 
 330 
Figure 2. Site of TB among migrant and non-migrant TB cases in the EU/EFTA, 1995-2017 331 
(n=1,270,896) 332 
EU/EFTA: European Union/European Free Trade Association, TB: tuberculosis 333 
Extrapulmonary TB defined as any case of TB involving organs or anatomical sites other than the lungs, 334 
with or without co-existent lung disease 335 






, p<0.001) 336 
Figure 3. Proportion of pulmonary and extrapulmonary TB among migrant and non-migrant TB 337 
cases in selected countries of the EU/EFTA, 1995-2017 338 
EU/EFTA: European Union/European Free Trade Association, TB: tuberculosis 339 
Extrapulmonary TB defined as any case of TB involving organs or anatomical sites other than the lungs, 340 
with or without co-existent lung disease 341 
The boxes in the figure illustrate the proportion of pulmonary and extrapulmonary TB cases that occur in 342 
migrants in each country. On the map, the different shadings of the countries represent the proportions 343 
of individuals with foreign citizenship living in that country on 1
st
 January 2016 (source: Eurostat, online 344 
data code: migr_pop1ctz).  345 
Figure 4. Site of TB among migrant TB cases in the EU/EFTA by region of origin, 1995-2017 346 
(n=261,074) 347 









Extrapulmonary TB defined as any case of TB involving organs or anatomical sites other than the lungs, 349 
with or without co-existent lung disease 350 
*p<0.001, a greater proportion of TB is pulmonary 351 
†<0.001, a greater propor\on of TB is extrapulmonary 352 
 p values are two-sided, calculated using one-sample test of proportion (H0 = the proportions of 353 
pulmonary and extrapulmonary TB are equal) 354 









Table 1. Characteristics of migrant and non-migrant TB cases in the EU/EFTA, 1995-2017 356 
(n=1,270,896) 357 
 Migrants Non-migrants Total 
n % n % n % 
Total 326,987 25.7 943,909 74.3 1,270,896 
Age 
Mean, SD 37.9 16.8 47.8  20.3 45.3 19.9 
Gender 
Female 130,944 40.1 320,536 34.0 451,480  35.6 
Male 195,264 59.9 622,902 66.0 818,166  64.4 
Region of origin 
Eastern Europe and Central 
Asia 
56,310 21.6 558,595 63.1 614,905 53.6 
Europe, North America and 
Oceania 
24,392 9.3 326,970 36.9 351,362 30.6 
Latin America and the 
Caribbean 
11,329 4.3 - 11,330 1.0 
Middle East and North Africa 9,399 3.6 - 9,405 0.8 
South-East Asia 89,303 34.2 - 89,353 7.8 
Sub-Saharan Africa 70,341 26.9 - 70,378  6.1 
Reporting region 
Eastern Europe 4,921  1.5 561,249 59.5 566,170 44.6 
Southern Europe 69,159 21.2 141,669 15.0 210,828 16.6 
Western Europe 128,360 39.3 122,157 12.9 250,517 19.7 
Northern Europe 124,547 38.1 118,834 12.6 243,381 19.2 
Previous TB diagnosis 
Yes 24,864 10.4 143,771 17.0 168,635 15.5 
No 213,423 89.6 703,879 83.0 917,302 84.5 
Site of TB 
Pulmonary 179,173 54.8 739,296 78.3 918,469 72.3 
Extrapulmonary 147,814 45.2 204,613 21.7 352,427  27.7 
EU/EFTA: European Union/European Free Trade Association, SD: standard deviation, TB: tuberculosis 358 
Extrapulmonary TB defined as any case of TB involving organs or anatomical sites other than the lungs, 359 
with or without co-existent lung disease 360 
Data reported as: n, % unless otherwise stated 361 
Sample sizes: Age, n=1,268,544; Gender, n=1,269,646; Region of origin, n=1,146,733; Reporting region, 362 









The difference between migrants and non-migrants for each characteristic is statistically significant at 364 
p<0.001 calculated using t test for continuous variables or χ
2




















Table 2. Site of TB among migrant and non-migrant extrapulmonary TB cases in the EU/EFTA, 370 
1995-2017 (n=251,681) 371 
 Migrants Non-migrants 
n % n % 
Lymphatic 37,150 47.6* 43,933 25.3 
Pleural 13,730 17.6† 73,052 42.1 
Bone/joint incl. spine 6,417  8.2* 12,513 7.2 
Disseminated 3,947  5.1* 8,245 4.8 
Genito-urinary 3,174  4.1† 11,547 6.7 
Peritoneal/digestive 3,091  4.0* 3,879 2.2 
CNS incl. meningitis 2,775  3.6* 5,835 3.4 
Other 7,793 10.0* 14,600 8.4 
Total 78,077 173,604 
CNS: central nervous system, EU/EFTA: European Union/European Free Trade Association, TB: 372 
tuberculosis 373 
Extrapulmonary TB defined as any case of TB involving organs or anatomical sites other than the lungs, 374 
with or without co-existent lung disease 375 
‘Other’ refers to TB infection in any organ or anatomical sites of the body that falls outside the categories 376 
above 377 
There are an additional 100,746 cases not reported here for which site of TB is known to be 378 
extrapulmonary, but exact site of TB is unknown 379 
* Proportion is higher in migrants 380 









Table 3. Site of TB among cases reported by countries in the Eastern, Southern, Western and 382 
Northern regions of the EU/EFTA, 1995-2017 (n=1,270,896) 383 
 Pulmonary TB Extrapulmonary TB Total 
n % n % n 
Eastern Europe 467,514 82.6 98,656 17.4* 566,170 
Migrant 3,994 81.2 927 18.8 4,921 
Non-migrant 463,520 82.6 97,729 17.4 561,249 
Southern Europe 148,347 70.4 62,481 29.6* 210,828 
Migrant 47,908 69.3 21,251 30.7 69,159 
Non-migrant 100,439 70.9 41,230 29.1 141,669 
Western Europe 161,019 64.3 89,498 35.7* 250,517 
Migrant 75,592 58.9 52,768 41.1 128,360 
Non-migrant 85,427 69.9 36,730 30.1 122,157 
Northern Europe 141,589 58.2 101,792 41.8* 243,381 
Migrant 51,679 41.5 72,868 58.5 124,547 
Non-migrant 89,910 75.7 28,924 24.3 118,834 
Total 918,469 72.3 352,427 27.7 1,270,896 
EU/EFTA: European Union/European Free Trade Association, TB: tuberculosis 384 
Extrapulmonary TB defined as any case of TB involving organs or anatomical sites other than the lungs, 385 
with or without co-existent lung disease 386 
*The difference in proportion of TB that is extrapulmonary between each region and each other region is 387 
significant at p<0.001, p values calculated using χ2, e.g. Eastern vs. Northern Europe χ2=5.4x104, p<0.001 388 Jo
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